Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (281-290 of 337) with videos related to

Pageof 34
Sort By:
Nature Communications|March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Annals of the New York Academy of Sciences|January 14, 2022
Innovative vaccine approaches-a Keystone Symposia reportJennifer Cable, Rino Rappuoli, Elizabeth J Klemm, et al.
BMJ (Clinical Research Ed.)|July 9, 2024
Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Philippa Davies, Derek Stewart, et al.
BMJ (Clinical Research Ed.)|July 9, 2024
Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Philippa Davies, Derek Stewart, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Eclinicalmedicine|October 25, 2023
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsOriana Ciani, Anthony M Manyara, Philippa Davies, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Pageof 34

Showing results (281-290 of 337) with videos related to

Sort By:
Pageof 34
Nature Communications|March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Annals of the New York Academy of Sciences|January 14, 2022
Innovative vaccine approaches-a Keystone Symposia reportJennifer Cable, Rino Rappuoli, Elizabeth J Klemm, et al.
BMJ (Clinical Research Ed.)|July 9, 2024
Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Philippa Davies, Derek Stewart, et al.
BMJ (Clinical Research Ed.)|July 9, 2024
Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaborationAnthony Muchai Manyara, Philippa Davies, Derek Stewart, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Eclinicalmedicine|October 25, 2023
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsOriana Ciani, Anthony M Manyara, Philippa Davies, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Pageof 34